HIV-1 Vaccine Enters Phase I Clinical Trial at National Institutes of Health (NIH)
GenVec, Inc. (Nasdaq: GNVC), announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has begun a Phase I clinical trial to test a novel vaccine known as Ad35HIV-EnvA to prevent HIV-1 infection.
This adenovector-based vaccine was developed under a collaborative research and development agreement (CRADA) between GenVec and the VRC.
The two-part Phase I clinical study is designed to evaluate the safety, tolerability and immunogenicity of the Ad35-EnvA vaccine in comparison to and in combination with the Ad5-EnvA vaccine in prime-boost schedules.
The first part of the study, a dose-escalation evaluation, will enroll 15 healthy adult volunteers. Three groups of five subjects each will receive one intramuscular injection of the vaccine at three different doses. Following vaccination of each dose group, an internal safety review will be conducted. The second phase of the study is designed to test prime-boost combinations of Ad5- and Ad35-based vaccines.
Additional information about GenVec is available at www.genvec.com.
SOURCE: GenVec, Inc.
You may also like to read
- Diabetes Vaccine Is Currently In A Phase II Trial
- Children With Rare Neurogenerative Disorder Will Undergo Phase I Clinical Trial Using Stem Cells
- Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
- National Institute of Health, USA Launches Undiagnosed Diseases Program
- End of Line for INGAP?
